| Basics |
Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Ltd is a biotechnology company developing novel RNA medicines. The company develops novel RNA medicines in therapeutic areas including infectious disease, cystic fibrosis, nonalcoholic steatohepatitis (NASH) and rare liver diseases.
|
| IPO Date: |
May 22, 2013 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$349.04M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$1.00 | 3.84%
|
| Avg Daily Range (30 D): |
$0.42 | 3.43%
|
| Avg Daily Range (90 D): |
$0.42 | 3.35%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.38M |
| Avg Daily Volume (30 D): |
.36M |
| Avg Daily Volume (90 D): |
.35M |
| Trade Size |
| Avg Trade Size (Sh.): |
65 |
| Avg Trade Size (Sh.) (30 D): |
48 |
| Avg Trade Size (Sh.) (90 D): |
53 |
| Institutional Trades |
| Total Inst.Trades: |
1,978 |
| Avg Inst. Trade: |
$2.09M |
| Avg Inst. Trade (30 D): |
$1.04M |
| Avg Inst. Trade (90 D): |
$.94M |
| Avg Inst. Trade Volume: |
.07M |
| Avg Inst. Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$2.37M |
| Avg Closing Trade (30 D): |
$1.04M |
| Avg Closing Trade (90 D): |
$.93M |
| Avg Closing Volume: |
78.29K |
|
|
| Financials |
| |
TTM |
Q1 2025 |
Q4 2024 |
|
Basic EPS
|
$-2.53
|
$-.52
|
$-1.11
|
|
Diluted EPS
|
$-2.52
|
$-.52
|
$-1.1
|
|
Revenue
|
$ 143.68M
|
$ 29.38M
|
$ 22.77M
|
|
Gross Profit
|
$
|
$
|
$
|
|
Net Income / Loss
|
$ -68.2M
|
$ -14.08M
|
$ -30.01M
|
|
Operating Income / Loss
|
$ -82.08M
|
$ -16.83M
|
$ -33.39M
|
|
Cost of Revenue
|
$
|
$
|
$
|
|
Net Cash Flow
|
$ -71.45M
|
$ -20.08M
|
$ -.15M
|
|
PE Ratio
|
|
|
|
|
|
|
